nach oben

Internal and Emergency Medicine

Erschienen in:

16.01.2021 | COVID-19 | IM - REVIEW Zur Zeit gratis

A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations

verfasst von: Arunkumar Krishnan, James P. Hamilton, Saleh A. Alqahtani, Tinsay A.Woreta

Erschienen in: Internal and Emergency Medicine | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Coronavirus disease 2019 (COVID-19) is an emerging infectious disease which has had a rapid surge in cases and deaths since it is first documented in Wuhan, China, in December 2019. COVID-19 is caused by the Betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 uses angiotensin-converting enzyme 2, which is highly expressed in the human lower respiratory tract but also in other tissues, as the cellular entry receptor. Thus, COVID-19 mainly affects the respiratory system but can cause damage to other body systems, including the cardiovascular, gastrointestinal, hepatobiliary, renal, and central nervous systems. We review the pathogenesis and clinical manifestations of the infection, focusing on our current understanding of the disease mechanisms and their translation to clinical outcomes, as well as adverse effects on different body systems. We also discuss the epidemiology pathogenesis, clinical, and multi-organ consequences, and highlight some of the research gaps regarding COVID-19.

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRefPubMedPubMedCentral

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19.Online: https://www.who.int/dg/speeches/detail/whodirector- general-s-opening-remarks-at-the-media-briefing-on-covid-19. Accessed 14 Aug 2020

Gorbalenya AE, Baker SC, Baric RS et al (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544. https://doi.org/10.1038/s41564-020-0695-zCrossRef

Novel Coronavirus (2019-nCoV) Situation Report – 22 (World Health Organization); https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf. Accessed 14 Aug 2020

. World Health Organization. Summary of probable SARS cases with onset of illness Geneva (Switzerland): World Health Organization; 2003 Dec. Available from: https://www.who.int/csr/sars/country/table2004_04_21/en. Accessed 14 Aug 2020

Zaki AM, Boheemen SV, Bestebroer TM, Osterhaus ADME, Fouchier RAM (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814–1820. https://doi.org/10.1056/NEJMoa1211721CrossRefPubMed

Liu Y, Gayle AA, Wilder-Smith A, Rocklov J (2020) The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. https://doi.org/10.1093/jtm/taaa021CrossRefPubMedPubMedCentral

Tang B, Wang X, Li Q et al (2020) Estimation of the transmission risk of the 2019-nCoV and its implication for public health interventions. J Clin Med 9:462. https://doi.org/10.3390/jcm9020462CrossRefPubMedCentral

Perlman S, Netland J (2009) Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7:439–450. https://doi.org/10.1038/nrmicro2147CrossRefPubMedPubMedCentral

10.

Villar J, Ferrando C, Martinez D et al (2020) Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 8:267–276. https://doi.org/10.1016/S2213-2600(19)30417-5CrossRefPubMed

11.

Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M (2006) Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev 127:274–281. https://doi.org/10.1016/j.mad.2005.11.001CrossRefPubMed

12.

Yang Y, Lu Q, Liu M et al (2020) Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. MedRxiv. https://doi.org/10.1101/2020.02.10.20021675CrossRefPubMedPubMedCentral

13.

Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061–1069. https://doi.org/10.1001/jama.2020.1585CrossRefPubMedPubMedCentral

14.

Wang W, Tang J, Wei F (2020) Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan. China J Med Virol 92:441–447. https://doi.org/10.1002/jmv.25689CrossRefPubMed

15.

Zou L, Ruan F, Huang M et al (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177–1179. https://doi.org/10.1056/NEJMc2001737CrossRefPubMedPubMedCentral

16.

Walls AC, Park YJ, Tortorici MA et al (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–292. https://doi.org/10.1016/j.cell.2020.02.058CrossRefPubMedPubMedCentral

17.

Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513. https://doi.org/10.1016/S0140-6736(20)30211-7CrossRefPubMedPubMedCentral

18.

Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 323:1239–1242. https://doi.org/10.1001/jama.2020.2648CrossRefPubMed

19.

Zou X, Chen K, Zou J et al (2020) Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 14:185–192. https://doi.org/10.1007/s11684-020-0754-0CrossRefPubMed

20.

Letko M, Marzi A, Munster V (2020) Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5:562–569. https://doi.org/10.1038/s41564-020-0688-yCrossRefPubMed

21.

Rabi FA, Al Zoubi MS, Kasasbeh GA et al (2020) SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens 9:231. https://doi.org/10.3390/pathogens9030231CrossRefPubMedCentral

22.

Simmons G, Zmora P, Gierer S et al (2013) Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res 100:605–614. https://doi.org/10.1016/j.antiviral.2013.09.028CrossRefPubMedPubMedCentral

23.

Paules CI, Marston HD, Fauci AS (2020) Coronavirus infections- More than just the common cold. JAMA 323:707–708. https://doi.org/10.1001/jama.2020.0757CrossRefPubMed

24.

. World Health Organization(2020). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva (Switzerland): World Health Organization;. Available from: https://www.who.int/docs/default-source/coronaviruse/who-chinajoint-mission-on-covid-19-final-report.pdf. Accessed 14 Aug 2020

25.

Yang J, Zheng Y, Gou X et al (2020) Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 94:91–95. https://doi.org/10.1016/j.ijid.2020.03.017CrossRefPubMedPubMedCentral

26.

Jin JM, Bai P, He W et al (2020) Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 8:152. https://doi.org/10.3389/fpubh.2020.00152CrossRefPubMedPubMedCentral

27.

Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032CrossRefPubMed

28.

Guo T, Fan Y, Chen et al (2020) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1017CrossRefPubMedPubMedCentral

29.

Fine P, Eames K, Heymann DL (2011) “Herd immunity”: a rough guide. Clin Infect Dis 52:911–916. https://doi.org/10.1093/cid/cir007CrossRefPubMed

30.

Richardson S, Hirsch JS, Narasimhan M et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 323:2052–2059. https://doi.org/10.1001/jama.2020.6775CrossRefPubMedPubMedCentral

31.

Lippi G, Wong J, Henry BM (2020) Hypertension and its severity or mortality in coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med 130:304–309. https://doi.org/10.20452/pamw.15272CrossRefPubMed

32.

Danser AHJ, Epstein M, Batlle D (2020) Renin–angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin–angiotensin system blockers. Hypertension 75:1382–1385. https://doi.org/10.1161/HYPERTENSIONAHA.120.15082CrossRefPubMed

33.

Zhang P, Zhu L, Cai J et al (2020) Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 126:1671–1681. https://doi.org/10.1161/CIRCRESAHA.120.31713CrossRefPubMedPubMedCentral

34.

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRefPubMedPubMedCentral

35.

Ludwig DS, Malley R. Americans are already too diseased to go back to work right now. https://www.nytimes.com/2020/03/30/opinion/obesity-us-healthcoronavirus.html. Accessed 14 Aug 2020

36.

.WHO. Global Health Obsevatory (GHO) data: overweight and obesity. 2017. who.int/gho/ncd/risk_factors/overweight_obesity/obesity_adults/en. Accessed 14 Aug 2020

37.

Guo L, Wei D, ZhangX WuYJ et al (2019) Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA Score. Front Microbiol 10:2752. https://doi.org/10.3389/fmicb.2019.02752CrossRefPubMedPubMedCentral

38.

Odegaard JI, Chawla A (2012) Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harbor Perspect Med 2:a007724. https://doi.org/10.1101/cshperspect.a007724CrossRef

39.

Dooley KE, Chaisson RE (2009) Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 9:737–746. https://doi.org/10.1016/S1473-3099(09)70282-8CrossRefPubMedPubMedCentral

40.

Cai H (2020) Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 8(4):e20. https://doi.org/10.1016/S2213-2600(20)30117-X (Erratum in: Lancet Respir Med 8:e26)CrossRefPubMedPubMedCentral

41.

US centers for disease control and prevention.coronavirus disease 2019 (COVID-19): people with certain medical conditions. 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medicalconditions.html. Accessed 14 Aug 2020

42.

Lala A, Johnson KW, Januzzi JL et al (2020) Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol 76:533–546. https://doi.org/10.1016/j.jacc.2020.06.007CrossRefPubMedPubMedCentral

43.

Emami A, Javanmardi F, Pirbonyeh N, Akbari A (2020) Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med 8:e35. https://doi.org/10.1371/journal.pone.0241265CrossRefPubMedPubMedCentral

44.

Farsalinos K, Barbouni A, Niaura R (2020) Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med 15:845–852. https://doi.org/10.1007/s11739-020-02355-7CrossRefPubMedPubMedCentral

45.

Han L, Ran J, Mak YW et al (2019) Smoking and influenza-associated morbidity and mortality: a systematic review and meta-analysis. Epidemiology 30:405–417. https://doi.org/10.1097/EDE.0000000000000984CrossRefPubMed

46.

Farsalinos K, Barbouni A, Poulas K et al (2020) Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis 11:2040622320935765. https://doi.org/10.1177/2040622320935765CrossRefPubMedPubMedCentral

47.

Polverino F (2020) Cigarette smoking and COVID-19: a complex interaction. Am J Respir Crit Care Med 202:471–472. https://doi.org/10.1164/rccm.202005-1646LECrossRefPubMedPubMedCentral

48.

Brake SJ, Barnsley K, Lu W et al (2020) Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J Clin Med 9:841. https://doi.org/10.3390/jcm9030841CrossRefPubMedCentral

49.

Sattar N, McInnes IB, McMurray JJV (2020) Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation 42:4–6. https://doi.org/10.1161/circulationaha.120.047659CrossRef

50.

Kalligeros M, Shehadeh F, Mylona EK et al (2020) Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity 28:1200–1204. https://doi.org/10.1002/oby.22859CrossRefPubMed

51.

Cai Q, Chen F, Wang T et al (2020) Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care 43:1392–1398. https://doi.org/10.2337/dc20-0576CrossRefPubMed

52.

Simonnet A, Chetboun M, Poissy J et al (2020) High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 28:1195–1199. https://doi.org/10.1002/oby.22831 (Epub 2020 Jun 10. Erratum in: Obesity (Silver Spring)) https://doi.org/10.1002/oby.22831)CrossRef

53.

Palaiodimos L, Kokkinidis DG, Li W et al (2020) Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx. New York Metabolism 108:154262. https://doi.org/10.1016/j.metabol.2020.154262CrossRefPubMed

54.

Peng YD, Meng K, Guan HQ et al (2020) Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi 48:450–455. https://doi.org/10.3760/cma.j.cn112148-20200220-00105CrossRefPubMed

55.

Zachariah P, Johnson CL, Halabi KC et al (2020) Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York city New York. JAMA Pediatr 174:e202430. https://doi.org/10.1001/jamapediatrics.2020.2430CrossRefPubMed

56.

Zhang F, Xiong Y, Wei Y et al (2020) Obesity predisposes to the risk of higher mortality in young COVID-19 patients. J Med Virol 92:2536–2542. https://doi.org/10.1002/jmv.26039CrossRefPubMed

57.

Caci G, Albini A, Malerba M et al (2020) COVID-19 and obesity: dangerous liaisons. J Clin Med 9:2511. https://doi.org/10.3390/jcm9082511CrossRefPubMedCentral

58.

Michalakis K, Ilias I (2020) SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. Diabetes Metab Syndr 14:469–471. https://doi.org/10.1016/j.dsx.2020.04.033CrossRefPubMedPubMedCentral

59.

Pedersen SF, Ho YC (2020) SARS-CoV-2: a storm is raging. J Clin Invest 130:2202–2205. https://doi.org/10.1172/JCI137647CrossRefPubMedPubMedCentral

60.

Diao B, Wang C, Tan Y et al (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 11:827. https://doi.org/10.3389/fimmu.2020.00827CrossRefPubMedPubMedCentral

61.

Stapleton RD, Dixon AE, Parsons PE et al (2010) The association between BMI and plasma cytokine levels in patients with acute lung injury. Chest 138:568–577. https://doi.org/10.1378/chest.10-0014CrossRefPubMedPubMedCentral

62.

Leal Vde O, Mafra D (2013) Adipokines in obesity. Clin Chim Acta 419:87–94. https://doi.org/10.1016/j.cca.2013.02.003CrossRefPubMed

63.

Almond MH, Edwards MR, Barclay WS, Johnston SL (2013) Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax 68:684–686. https://doi.org/10.1136/thoraxjnl-2012-203009CrossRefPubMed

64.

Li B, Yang J, Zhao F et al (2020) Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 109:531–538. https://doi.org/10.1007/s00392-020-01626-9CrossRefPubMed

65.

Lippi G, Plebani M (2020) Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 58:1131–1134. https://doi.org/10.1515/cclm-2020-0198CrossRefPubMed

66.

Wong CK, Lam CWK, Wu AKL et al (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136:95–103. https://doi.org/10.1111/j.1365-2249.2004.02415.xCrossRefPubMedPubMedCentral

67.

Ronco C, Reis T (2020) Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol 16:308–310. https://doi.org/10.1038/s41581-020-0284-7CrossRefPubMed

68.

Badawi A, Ryoo SG (2016) Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis 49:129–133. https://doi.org/10.1016/j.ijid.2016.06.015CrossRefPubMedPubMedCentral

69.

Liu K, Fang YY, Deng Y et al (2020) Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 133:1025–1031. https://doi.org/10.1097/CM9.0000000000000744CrossRef

70.

Zhang C, Shi L, Wang FS (2020) Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 5:428–430. https://doi.org/10.1016/S2468-1253(20)30057-1CrossRefPubMedPubMedCentral

71.

Hirsch JS, Ng JH, Ross DW et al (2020) Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 98:209–218. https://doi.org/10.1016/j.kint.2020.05.006CrossRefPubMedPubMedCentral

72.

Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infect 80:607–613. https://doi.org/10.1016/j.jinf.2020.03.037CrossRefPubMedPubMedCentral

73.

Zhang ZL, Hou YL, Li DT, Li FZ (2020) Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Investig 80:441–447. https://doi.org/10.1080/00365513.2020.1768587CrossRef

74.

Aziz M, Fatima R, Assaly R (2020) Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Viro. https://doi.org/10.1002/jmv.25948CrossRef

75.

Cheng Y, Luo R, Wang K et al (2020) Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 97:829–838. https://doi.org/10.1016/j.kint.2020.03.005CrossRefPubMedPubMedCentral

76.

Bahl A, Van Baalen MN, Ortiz L et al (2020) Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort. Intern Emerg Med 15:1485–1499. https://doi.org/10.1007/s11739-020-02509-7CrossRefPubMedPubMedCentral

77.

Ronco C, Reis T, Husain-Syed F (2020) Management of acute kidney injury in patients with COVID-19. Lancet Respir Med 8:738–742. https://doi.org/10.1016/S2213-2600(20)30229-0CrossRefPubMedPubMedCentral

78.

Wu C, Chen X, Cai Y et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:1–11. https://doi.org/10.1001/jamainternmed.2020.0994CrossRefPubMedCentral

79.

Alberici F, Delbarba E, Manenti C et al (2020) Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. Kidney Int Rep 5:580–585. https://doi.org/10.1016/j.ekir.2020.04.001CrossRefPubMedPubMedCentral

80.

Cummings MJ, Baldwin MR, Abrams D et al (2020) Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 395:1763–1770. https://doi.org/10.1016/S0140-6736(20)31189-2CrossRefPubMedPubMedCentral

81.

Holshue ML, DeBolt C, Lindquist S et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929–936. https://doi.org/10.1056/NEJMoa2001191CrossRefPubMedPubMedCentral

82.

Zhang JJ, Dong X, Cao YY (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75:1730–1741. https://doi.org/10.1111/all.14238CrossRefPubMed

83.

Gu J, Han B, Wang J (2020) COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 158:1518–1519. https://doi.org/10.1053/j.gastro.2020.02.054CrossRefPubMed

84.

Cheung KS, Hung IFN, Chan PPY et al (2020) Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a hong kong cohort: systematic review and meta-analysis. Gastroenterology 159:81–95. https://doi.org/10.1053/j.gastro.2020.03.065CrossRefPubMed

85.

Jiang M, Li H, Zhang Y et al (2017) Transitional basal cells at the squamous-columnar junction generate Barrett’s oesophagus. Nature 550:529–533. https://doi.org/10.1038/nature24269CrossRefPubMedPubMedCentral

86.

Haber AL, Biton M, Rogel N et al (2017) A single-cell survey of the small intestinal epithelium. Nature 551:333–339. https://doi.org/10.1038/nature24489CrossRefPubMedPubMedCentral

87.

Xiao F, Tang M, Zheng X et al (2020) Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 158:1831–1833. https://doi.org/10.1053/j.gastro.2020.02.055CrossRefPubMed

88.

Hashimoto T, Perlot T, Rehman A et al (2012) ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487:477–481. https://doi.org/10.1038/nature11228CrossRefPubMedPubMedCentral

89.

Wong SH, Lui RN, Sung JJ (2020) Covid-19 and the digestive system. J Gastroenterol Hepatol 35:744–748. https://doi.org/10.1111/jgh.15047CrossRefPubMed

90.

Gao QY, Chen YX, Fang JY (2020) Novel coronavirus infection and gastrointestinal tract. J Dig Dis 21:125–126. https://doi.org/10.1111/1751-2980.12851CrossRefPubMedPubMedCentral

91.

Chai X, Hu L, Zhang Y et al (2020) Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. https://doi.org/10.1101/2020.02.03.931766CrossRef

92.

Mantovani A, Beatrice G, Dalbeni A (2020) Coronavirus disease 2019 (COVID-19) and prevalence of chronic liver disease: a meta-analysis. Liver Int 40:1316–1320. https://doi.org/10.1111/liv.14465CrossRefPubMed

93.

Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q (2020) Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology 159:367–370. https://doi.org/10.1053/j.gastro.2020.03.055CrossRefPubMed

94.

Yang JK, Lin SS, Ji XJ, Guo LM (2010) Binding of SARS coronavirus to its receptor damages islets and causes. Acta Diabetol 47:193–199. https://doi.org/10.1007/s00592-009-0109-4CrossRefPubMed

95.

Helms J, Kremer S, Merdji H et al (2020) Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382:2268–2270. https://doi.org/10.1056/NEJMc2008597CrossRefPubMed

96.

Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0CrossRefPubMedPubMedCentral

97.

Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 7:683–690. https://doi.org/10.1001/jamaneurol.2020.1127CrossRef

98.

Aiello F, Gabriele Gallo Afflitto GG, Mancino R et al (2020) Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review. Eye 34:1206–1211. https://doi.org/10.1038/s41433-020-0926-9CrossRefPubMed

99.

Wang J, Wang P, Li C, Huang Y, Yang C, Zhang L (2020) Central neurological complications and potential neuropathogenesis of COVID-19. Intern Emerg Med 29:1–4. https://doi.org/10.1007/s11739-020-02476-zCrossRef

100.

Zubair AS, McAlpine LS, Gardin T et al (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 77:1018–1027. https://doi.org/10.1001/jamaneurol.2020.2065CrossRefPubMedPubMedCentral

101.

Wollina U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T (2020) Cutaneous signs in COVID-19 patients: a review. Dermatol Ther. https://doi.org/10.1111/dth.13549CrossRefPubMedPubMedCentral

102.

Gupta A, Madhavan MV, Sehgal K et al (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26:1017–1032. https://doi.org/10.1038/s41591-020-0968-3CrossRefPubMed

103.

Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F (2020) COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.16778CrossRefPubMedPubMedCentral

104.

Recalcati S (2020) Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 34:212–213. https://doi.org/10.1111/jdv.16387CrossRef

105.

Grzegrzolka S, Pula B, Zamirska A et al (2013) ACE and ACE2 expression innormal and malignant skin lesions. Folia Histochem Cytobiol 51:232–238. https://doi.org/10.5603/FHC.2013.0033CrossRefPubMed

106.

Wei C, Friedman AJ (2020) COVID-19 pandemic: are there unique cutaneous manifestations in patients infected with SARS-CoV-2? J Drugs Dermatol 19:554–555PubMed

107.

Recalcati S, Barbagallo T, Frasin LA et al (2020) Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol 34:e346–e347. https://doi.org/10.1111/jdv.16533CrossRefPubMed

108.

Dashraath P, Wong JLJ, Lim MXK et al (2020) Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy. Am J Obstet Gynecol 222:521–531. https://doi.org/10.1016/j.ajog.2020.03.021CrossRefPubMedPubMedCentral

109.

Mascio DD, Khalil A, Gabriele Saccone G et al (2020) Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2:100107. https://doi.org/10.1016/j.ajogmf.2020.100107CrossRefPubMedPubMedCentral

110.

Dong L, Tian J, He S et al (2020) Possible vertical transmission of SARSCoV-2 from an infected mother to her newborn. JAMA 323:1846–1848. https://doi.org/10.1001/jama.2020.4621CrossRefPubMedPubMedCentral

111.

Zeng H, Xu C, Fan J et al (2020) Antibodies in infants born to mothers with COVID-19 pneumonia. JAMA 32:1848–1849. https://doi.org/10.1001/jama.2020.4861CrossRef

112.

da Silva SJR, Silva CTAD, Guarines KM et al (2020) Clinical and laboratory diagnosis of SARS-CoV-2, the virus causing COVID-19. ACS Infect Dis 6:2319–2336. https://doi.org/10.1021/acsinfecdis.0c00274CrossRefPubMed

113.

Jin YH, Cai L, Cheng ZS et al (2020) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 7:4. https://doi.org/10.1186/s40779-020-0233-6CrossRefPubMedPubMedCentral

114.

. National health commission of the People’s Republic of China. Diagnosis and treatment of new coronavirus pneumonia (version 7) 2020; http://www.nhc.gov.cn/. Accessed 14 Aug 2020

115.

Chung M, Bernheim A, Mei X et al (2020) CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 295:202–207. https://doi.org/10.1148/radiol.2020200230CrossRefPubMed

116.

Kanne JP, Little BP, Chung JH, Elicker BM, Loren H, Ketai LH (2020) Essentials for radiologists on COVID-19: an update radiology scientific expert panel. Radiology 296:E113–E114. https://doi.org/10.1148/radiol.2020200527CrossRefPubMed

117.

Ng MY, Lee EYP, Jin Yang J et al (2020) Imaging profile of the COVID-19 infection: radiologic findings and literature review. Radiol Cardiothorac Imag 2:e200034. https://doi.org/10.1148/ryct.2020200034CrossRef

118.

Bernheim A, Mei X, Huang M et al (2020) Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 295:200463. https://doi.org/10.1148/radiol.2020200463CrossRefPubMed

119.

Nair A, Rodrigues JCL, Hare S et al (2020) A British Society of Thoracic Imaging statement: considerations in designing local imaging diagnostic algorithms for the COVID-19 pandemic. Clin Radiol 75:329–334. https://doi.org/10.1016/j.crad.2020.03.008CrossRefPubMedPubMedCentral

120.

Shi H, Han X, Jiang N et al (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 20:425–434. https://doi.org/10.1016/S1473-3099(20)30086-4CrossRefPubMedPubMedCentral

121.

. Burrell CJ, Howard CR, Murphy FA (2016). Fenner and White's Medical Virology 5th Edition. United States: Academic Press: ISBN: 9780123751577

122.

. WHO. Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance,.WHO/COVID19/laboratory/2020.5. World Health Organization. Accessed 14 Aug 2020

123.

Bai HX, Hsieh B, Xiong Z et al (2020) Performance of radiologists in differentiating COVID-19 from non-COVID-19 viral pneumonia at chest CT. Radiology 296:E46–E54. https://doi.org/10.1148/radiol.2020200823CrossRefPubMed

Titel: A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations
verfasst von: Arunkumar Krishnan
James P. Hamilton
Saleh A. Alqahtani
Tinsay A.Woreta
Publikationsdatum: 16.01.2021
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Internal and Emergency Medicine / Ausgabe 4/2021
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02616-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI)

Clam ingestion: unusual cause of large bowel obstruction

Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs

Clinical outcomes of drug-eluting balloon for treatment of small coronary artery in patients with acute myocardial infarction: comment

A risk score model to predict in-hospital mortality of patients with end-stage renal disease and acute myocardial infarction

The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis